Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 6/20 | 0.43 |
| ▸ | RAF1 | P04049 | 4/20 | 0.43 |
| ▸ | BRAF | P15056 | 4/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125220 | 0.96 | RAF1 (0.45) | FGFR1SRCMAP3K7RAF1BRAF | |
| SCHEMBL14137249 | 0.88 | MAP3K7 (0.43) | MAP3K7RAF1BRAFCSF1RDDR1 | |
| SCHEMBL2234812 | 0.86 | RAF1 (0.56) | RAF1BRAFCSF1RDDR1DDR2 | |
| SCHEMBL2233512 | 0.84 | FGFR1 (0.48) | FGFR1SRCMAP3K7BRAFFGFR3 | |
| SCHEMBL2235550 | 0.84 | FGFR3 (0.53) | FGFR1SRCRAF1BRAFFGFR3 | |
| SCHEMBL2234789 | 0.84 | FGFR3 (0.47) | FGFR1SRCMAP3K7FGFR3CYP3A4 | |
| SCHEMBL2232574 | 0.84 | RAF1 (0.48) | MAP3K7RAF1BRAFCSF1RDDR1 | |
| SCHEMBL2232776 | 0.83 | FGFR1 (0.45) | FGFR1SRCMAP3K7RAF1BRAF | |
| SCHEMBL2232775 | 0.83 | RAF1 (0.46) | FGFR1RAF1BRAFFGFR3CSF1R | |
| SCHEMBL20895036 | 0.83 | FGFR3 (0.48) | FGFR1SRCMAP3K7RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | disclosed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | disclosed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | disclosed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | FGFR1 285/4885SRC 86/4885MAP3K7 17/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | FGFR1 285/4885SRC 86/4885MAP3K7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.